title: Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation.
abstract: IL-8 has been characterized primarily as a polymorphonuclear leukocyte (PMN) chemoattractant and proinflammatory mediator. Recently, we have reported that [Ala-IL-8]77 is secreted by activated cultured human endothelial cells and can function as a potent inhibitor of PMN adhesion to these monolayers. The pathophysiologic relevance of this in vitro observation was examined by determining the effects of intravascular or extravascular administration of IL-8 on PMN emigration at sites of acute inflammation in the skin of NZW rabbits. An i.v. bolus of [Ala-IL-8]77 (12 micrograms/kg) produced a marked and selective reduction of circulating PMN within 3 min, which returned toward preinjection levels within 30 min, and subsequently exceeded this level. A similar response was observed for circulating radiolabeled PMN, and gamma-scintigraphy determined that the lungs were the primary site of leukosequestration. During the 30- to 150-min interval after i.v. infusion of [Ala-IL-8]77, PMN emigration into acute inflammatory sites, elicited by various chemoattractants or cytokines, was significantly reduced, as judged histologically and quantitated with 51Cr-labeled PMN and myeloperoxidase measurements. Intravenous administration of [Ser-IL-8]72 yielded similar results. This inhibitory effect of i.v. IL-8 was transient and reinducible and did not reflect a suppression of the responsiveness of circulating PMN to chemoattractants. Intradermal injections of [Ala-IL-8]77 or [Ser-IL-8]72 induced dose-dependent PMN accumulation, which also was significantly reduced by i.v. administration of either form of IL-8. These results indicate that i.v. IL-8 can function as a PMN-directed leukocyte adhesion inhibitor and suggest that local secretion of IL-8 by activated endothelium may differentially modulate leukocyte-endothelial interactions at sites of acute inflammation.
authors.affiliation: Department of Pathology, Brigham and Women's Hospital, Boston, MA.
authors.forename: D H
authors.initials: DH
authors.lastname: Hechtman
authors.forename: M I
authors.initials: MI
authors.lastname: Cybulsky
authors.forename: H J
authors.initials: HJ
authors.lastname: Fuchs
authors.forename: J B
authors.initials: JB
authors.lastname: Baker
authors.forename: M A
authors.initials: MA
authors.lastname: Gimbrone
mesh_terms: D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D002630:Chemotactic Factors; D015936:Complement C5a / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007249:Inflammation / Q000276:immunology*; D007275:Injections, Intravenous; D007375:Interleukin-1 / Q000494:pharmacology; D016209:Interleukin-8 / Q000494:pharmacology*; D007975:Leukotriene B4 / Q000494:pharmacology; D008297:Male; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000502:physiology*; D011817:Rabbits; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D002630:Chemotactic Factors; D007375:Interleukin-1; D016209:Interleukin-8; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; D015936:Complement C5a